Octasomy 21 in a patient with secondary AML after CMML: the role of acquired NRAS mutations in triggering aneuploidy

Leuk Lymphoma. 2018 Oct;59(10):2478-2481. doi: 10.1080/10428194.2018.1427861. Epub 2018 Jan 31.

Authors

Kathrin Thomay¹, Yvonne Lisa Behrens¹, Jana Lentes¹, Nicole Wittner¹, Verena Wittig¹, Doreen Rothe¹, Doris Steinemann¹, Brigitte Schlegelberger¹, Gudrun Göhring¹

Affiliation

¹ a Department of Human Genetics , Hannover Medical School , Hannover , Germany.

PMID: 29384408
DOI: 10.1080/10428194.2018.1427861

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Aneuploidy*
Antimetabolites, Antineoplastic / therapeutic use
Azacitidine / therapeutic use
Chromosomes, Human, Pair 21 / genetics*
Erythropoietin / therapeutic use
Fatal Outcome
GTP Phosphohydrolases / genetics*
Granulocyte Colony-Stimulating Factor / therapeutic use
Humans
Karyotyping
Leukemia, Myeloid, Acute / drug therapy
Leukemia, Myeloid, Acute / genetics*
Leukemia, Myelomonocytic, Chronic / drug therapy
Leukemia, Myelomonocytic, Chronic / genetics
Male
Membrane Proteins / genetics*
Neoplasms, Second Primary / genetics*

Substances

Antimetabolites, Antineoplastic
Membrane Proteins
Erythropoietin
Granulocyte Colony-Stimulating Factor
GTP Phosphohydrolases
NRAS protein, human
Azacitidine